Neurocrine Biosciences

Neurocrine Biosciences
Public NASDAQ: NBIX
Industry Biotechnology
Founded 1992
Headquarters San Diego, California, U.S.
Key people
 Bill Rastetter, Chairman
Kevin C. Gorman, CEO/President
Number of employees
 95 (2015)
Website www.neurocrine.com

Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.

Medications

On May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner Pfizer. As a result of the denial, the stock price fell significantly and the company laid off 300 employees in 2006. In 2007 Neurocrine showed a a fourth quarter loss of $128 million, including a $94 million write-off, with a further layoff of half the remaining workforce.[1]

In 2010 the company announced that its drug to treat endometriosis had achieved its main and secondary goals in a study. The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse.[2] As of 2016 the drug, being developed in cooperation with AbbVie, is in phase III clinical trials.[3]

As of 2016 the company has a drug in development, called Ingrezza, for treatment of tardive dyskinesia. There are currently no approved treatments for this condition. The United States Food and Drug Administration has agreed to review the drug's application under fast-track priority status.[4]

References

  1. ↑ "Write-Off Swells Neurocrine's 4Q Loss". Associated Press. 2008-02-05.
  2. ↑ "Neurocrine Biosciences Shares Soar on Drug Trial". FOXBusiness. 2010-05-25.
  3. ↑ Moore, Charles (August 25, 2016). "Endometriosis Therapy Candidate Elagolix Meeting Phase 3 Clinical Trial Primary Targets". Endometriosis News. Retrieved 14 October 2016.
  4. ↑ Meiling, Brittany (October 11, 2016). "FDA Accepts Neurocrine Biosciences' New Drug Application". San Diego Business Journal. Retrieved 14 October 2016.


This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.